Logo

Blood cancer care is
always advancing.
Aim higher with
clonoSEQ®.

Explore real-world data

All 32 NCCN® Member Institutions use clonoSEQ to track MRD at a sensitivity of 10-6.1,2* Use clonoSEQ in routine clinical practice to help predict patient outcomes and support treatment decisions in lymphoid malignancies.3-9

JOIN THE MOVEMENT AND DETECT DEEPER

*Given adequate sample material.

Is MRD testing part of your standard practice?
Why many clinicians make clonoSEQ standard in their practice.

clonoSEQ leverages the power of next-generation sequencing (NGS) to help clinicians monitor MRD throughout the course of multiple myeloma, CLL, and B-ALL care.1

1

Widely trusted

clonoSEQ is a mainstay of leading clinicians, including at all 32 NCCN® centers and hundreds of academic institutions and community clinics2

2

Broadly utilized

MRD assessment can be used throughout care, including during induction, maintenance, transplant, consolidation, and after treatment10-13

3

Highly sensitive

clonoSEQ technology can measure MRD at a sensitivity of 10-6 with adequate sample material1

4

Extensively accessible

Reimbursed by CMS and national plans covering >240 million lives (myeloma, ALL) and >150 million lives (CLL). Support for OOP costs is available for qualifying patients through Adaptive Assist™2

Discover specimen requirements, report tutorials, reimbursement support services for patients, and more

Download resources

News and updates

Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

Adaptive Biotechnologies Corporation announced today new data highlighting the clinical utility of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) in patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).

VIEW PRESS RELEASE

September, 2021

Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status

VIEW PRESS RELEASE


This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

References

  • clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020. https://www.clonoseq.com/technical-summary/
  • Data on file. Adaptive Biotechnologies. 2021.
  • Munshi N, et al. Blood Adv. 2020;4(23):59‌88-5‌999.
  • Berry D, et al. JAMA Oncol. 2017;3(7):e170‌580.
  • Molica S, et al. Clin Lymphoma Myeloma Leuk. 2019;19(7):423-430.
  • San-Miguel J, et al. Blood. 2021. doi: 10.1182/blood.2020010439
  • Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  • Friend B, et al. Pediatr Blood Cancer. 2020. doi: 10.1002/pbc.28079
  • Al-Sawaf O, et al. J Clin Oncol. 2021. doi: 10.1200/JCO.21.01181
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed November 1, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.4.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed October 26, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Acute Lymphoblastic Leukemia V.1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed November 4, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed October 26, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.